Manidipine:回顾其在高血压中使用。

文章的细节

引用

复制到剪贴板

SM带来欢乐,麦克莱伦K

Manidipine:回顾其在高血压中使用。

药。2001;61 (12):1777 - 99。

PubMed ID

11693466 (在PubMed

]

文摘

Manidipine dihydropyridine钙拮抗剂,导致系统性血管舒张通过抑制平滑肌细胞的内压敏电阻器钙电流。由此产生的降低高血压患者的血压(BP)保持在24小时。Manidipine 10至40毫克每日4周显著降低办公室从基线和与安慰剂相比,英国石油公司BP和显著降低24小时与安慰剂比较原发性高血压患者的对照试验。英国石油公司保持在24小时的下降(槽峰值BP率> 50%)没有扰乱生理BP模式。英国石油公司减少的治疗剂量manidipine维持长达1年noncomparative试验。manidipine BP-lowering容量的5到20毫克/天似乎是类似于其他钙拮抗剂与它比较随机双盲和nonblind审判。在短期内控制试验,manidipine 10毫克每日显著降低槽坐在BP与安慰剂比较老年患者轻度至中度原发性高血压。减少在英国石油公司保持三年的治疗。药物(10或20 mglday)也显著降低BP从基线坐在高血压和2型糖尿病患者在随机,长期比较试验。在一般情况下,观察到降低BP与manidipine类似观察氨氯地平,卡托普利或delapril。 The effects of manidipine on urinary albumin excretion (UAE) have not been clearly demonstrated in clinical trials in this patient group. BP was also reduced with manidipine in patients with impaired glucose tolerance. Manidipine was well tolerated in clinical trials, with most adverse effects related to vasodilation. Commonly reported events included ankle oedema, headache. palpitation. flushing, dizziness, rash and fatigue. Manidipine appears to have less potential for pedal oedema than amlodipine. CONCLUSIONS: Manidipine has shown antihypertensive efficacy and appears to be well tolerated in adult and elderly patients with mild or moderate essential hypertension. The BP-lowering effects of the drug in patients with hypertension and type 2 diabetes mellitus or impaired glucose tolerance were not associated with any adverse metabolic effects. The effects of manidipine on UAE in this patient group remain unclear. Manidipine provides an additional treatment option for patients for whom dihydropyridine calcium antagonists are appropriate. Manidipine is a dihydropyridine calcium antagonist, which causes systemic vasodilation by inhibiting the voltage-dependent calcium inward currents in smooth muscle cells. The resulting reduction in blood pressure (BP) in patients with hypertension is maintained over 24 hours. Manidipine 10 to 40mg once daily for 4 weeks significantly lowered office BP from baseline and compared with placebo, and significantly reduced 24-hour BP compared with placebo in patients with essential hypertension in a well controlled trial. The decline in BP was maintained over 24 hours (trough to peak BP ratios were >50%) without disturbing the circadian BP pattern. BP reductions with therapeutic dosages of manidipine were maintained for up to 1 year in non-comparative trials. The BP-lowering capacity of manidipine 5 to 20 mg/day appears to be similar to that of other calcium antagonists with which it has been compared in randomised double-blind and nonblind trial. In a well controlled short term trial, manidipine 10 mg daily significantly decreased trough sitting BP compared with placebo in elderly patients with mild to moderate essential hypertension. Decreases in BP were maintained for up to 3 years of treatment. The drug (10 or 20 mg/day) also significantly lowered sitting BP from baseline in patients with hypertension and type 2 diabetes mellitus in randomised, long term comparative trials. In general, the observed reduction in BP with manidipine was similar to that observed with amlodipine, enalapril or delapril. The effects of manidipine on urinary albumin excretion (UAE) have not been clearly demonstrated in clinical trials in this patient group. BP was also reduced with manidipine in patients with impaired glucose tolerance. Manidipine was well tolerated in clinical trials, with most adverse effects related to vasodilation. Commonly reported events included ankle oedema, headache. palpitation. flushing, dizziness, rash and fatigue. Manidipine appears to have less potential for pedal oedema than amlodipine. CONCLUSIONS: Manidipine has shown antihypertensive efficacy and appears to be well tolerated in adult and elderly patients with mild or mo

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Manidipine